Free tool
FAERS Monitor: Orserdu
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217639 or its brand name (Orserdu, Elacestrant Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,181
Serious
2,423
34% of reports
Hospitalization
906
Death reported
553
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea1,512
- fatigue1,130
- disease progression783
- vomiting694
- diarrhoea566
- death520
- drug ineffective491
- constipation408
- product dose omission issue382
- decreased appetite377
- pain374
- arthralgia342
- asthenia249
- dyspepsia240
- abdominal discomfort238
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3,022 |
| 2024 | 3,662 |
| 2025 | 330 |
| 2026 | 162 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,978 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease progressionSignal | 783 | 19.5 | 18.3 | 13,714 |
| dyspepsiaSignal | 240 | 7.2 | 6.3 | 1,269 |
| nauseaSignal | 1,512 | 5.6 | 5.4 | 5,927 |
| constipationSignal | 408 | 5.5 | 5.0 | 1,506 |
| decreased appetiteSignal | 377 | 4.8 | 4.3 | 1,127 |
| vomitingSignal | 694 | 4.3 | 4.0 | 1,811 |
| fatigueSignal | 1,130 | 4.3 | 4.0 | 2,915 |
| abdominal discomfortSignal | 238 | 4.2 | 3.7 | 572 |
| product dose omission issueSignal | 382 | 3.8 | 3.5 | 798 |
| diarrhoeaSignal | 566 | 2.6 | 2.4 | 558 |
| arthralgiaSignal | 342 | 2.4 | 2.2 | 286 |
| asthenia | 249 | 1.9 | 1.7 | 114 |
| pain | 374 | 1.8 | 1.6 | 132 |
| death | 520 | 1.8 | 1.6 | 180 |
| drug ineffective | 491 | 1.1 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.